Notwithstanding encouraging clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial difficulty from PBMs. These companies are often building barriers to access, like significant expense requirements and PA that restric